Sutro Biopharma (NASDAQ:STRO) Given Market Outperform Rating at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Sutro Biopharma (NASDAQ:STRO) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $17.00 price target on the stock.

Other equities research analysts also recently issued reports about the company. Wedbush restated an “outperform” rating and set a $8.00 price objective on shares of Sutro Biopharma in a research report on Tuesday. Piper Sandler restated an “overweight” rating and set a $11.00 price objective on shares of Sutro Biopharma in a research report on Friday, October 11th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Sutro Biopharma in a research report on Monday, November 18th. Finally, Truist Financial reduced their price target on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 16th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.13.

Sutro Biopharma Trading Down 3.6 %

NASDAQ:STRO opened at $2.12 on Wednesday. The company has a market capitalization of $174.82 million, a P/E ratio of -1.32 and a beta of 1.09. Sutro Biopharma has a 12 month low of $2.08 and a 12 month high of $6.13. The business’s 50-day moving average is $3.26 and its 200 day moving average is $3.62.

Institutional Investors Weigh In On Sutro Biopharma

A number of institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its position in Sutro Biopharma by 24.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock worth $102,000 after buying an additional 3,578 shares during the period. ProShare Advisors LLC raised its stake in Sutro Biopharma by 49.1% during the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock worth $48,000 after purchasing an additional 5,373 shares during the period. Hsbc Holdings PLC raised its stake in Sutro Biopharma by 9.7% during the second quarter. Hsbc Holdings PLC now owns 60,858 shares of the company’s stock worth $173,000 after purchasing an additional 5,404 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Sutro Biopharma by 27.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock valued at $97,000 after acquiring an additional 7,082 shares during the period. Finally, Gladius Capital Management LP acquired a new stake in Sutro Biopharma during the 3rd quarter valued at $28,000. 96.99% of the stock is currently owned by institutional investors and hedge funds.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.